TABLE 1.
Distribution of patients’ characteristics and their association with incident AF among COVID‐19 study population
| Incident AF free group | Incident AF group | Univariable | Multivariable | |
|---|---|---|---|---|
| RR (CI), P value | RR (CI), P value | |||
| n | 343 | 71 | ||
| Male gender, n (%) | 207 (60.3) | 46 (64.8) | 1.17 (0.75,1.76), P: .485 | ‐ |
| Age (mean (SD)) | 65.54 (15.48) | 73.69 (9.90) | 1.04 (1.02,1.05), P < .001 | 1.03 (1.01,1.05), P: .002 |
| Smoker, n (%) | 63 (18.4) | 21 (29.6) | 1.62 (1.02, 2.36), P: .035 | NS |
| Hypertension, n (%) | 206 (60.2) | 57 (80.3) | 2.08 (1.37, 3.02), P: .002 | NS |
| Diabetes, n (%) | 84 (24.6) | 22 (31.0) | 1.29 (0.81, 1.93), P: .261 | ‐ |
| Dyslipidaemia, n (%) | 94 (27.5) | 24 (33.8) | 1.27 (0.80, 1.88), P: .285 | ‐ |
| Obesity, n (%) | 24 (13.3) | 5 (10.6) | 0.82 (0.30, 1.67), P: .632 | ‐ |
| History of AF, n (%) | 51 (15.0) | 21 (29.6) | 1.93 (1.24, 2.73), P: .004 | NS |
| Heart Failure, n (%) | 29 (8.5) | 17 (23.9) | 2.41 (1.53, 3.35), P < .001 | 1.88 (1.09, 2.86), P: .023 |
| Previous Stroke, n (%) | 25 (7.3) | 10 (14.1) | 1.75 (0.92, 2.78), P: .068 | NS |
| CKD, n (%) | 47 (13.8) | 17 (23.9) | 1.69 (0.61, 5.80), P: .034 | NS |
| CAD, n (%) | 45 (13.2) | 21 (29.6) | 2.12 (1.38, 2.96), P < .001 | 1.75 (1.07, 2.59), P: .024 |
| COPD, n (%) | 65 (19.0) | 23 (32.4) | 1.73 (1.12, 2.48), P: .134 | ‐ |
| ACEI/ARBs, n (%) | 132 (41.4) | 38 (55.9) | 1.57 (1.05, 2.25), P: .030 | NS |
| Ca‐Antagonists, n (%) | 79 (23.0) | 21 (29.6) | 1.32 (0.83, 2.08), P: .236 | ‐ |
| Beta‐Blockers, n (%) | 46 (13.4) | 12 (16.9) | 0.95 (0.83, 1.09), P: .477 | ‐ |
| Incident VT, n (%) | 7 (2.0) | 7 (9.9) | 3.04 (1.55, 4.47), P: .003 | 2.94 (1.37, 4.49), P: .008 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; AF atrial fibrillation; ARBs, angiotensin II receptor blockers; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DCM dilated cardiomyopathy; VT, ventricular tachycardia.